Full-Time

Associate Director

Clinical Business Operations Management

Iovance Biotherapeutics

Iovance Biotherapeutics

501-1,000 employees

TIL-based T-cell therapies for solid tumors

Compensation Overview

$175k - $195k/yr

Remote in USA

Remote

Category
Business & Strategy (1)
Required Skills
Agile
Six Sigma
biostatistics
Data Analysis
Requirements
  • A bachelor’s degree or equivalent curriculum in life science, learning science, or other relevant healthcare discipline is required, and an advanced degree such as a Master of Business Administration is preferred.
  • A minimum of ten years in the pharmaceutical industry with responsibilities within a drug development organization, with emphasis in business and project management, is preferred.
  • Excellent written and oral communication skills, including strong presentation skills, are required.
  • Strong and proven project management skills and being very organized are required.
  • Adept at fostering positive, transparent, and productive relationships is required.
  • Ability to adapt quickly to rapidly changing business demands is required.
  • Takes initiative to solve a wide range of difficult problems in creative ways is required.
  • Proven ability to challenge current business standards and processes, with the ability to propose solutions, is required.
  • Embraces an enterprise mindset and can clearly connect functional activities to the broader organizational context is required.
  • Proficiency with core business management areas including strategic planning, business process management and improvement, project management, team facilitation, and communication and event planning is required.
  • Experience in managing organizational cross-functional initiatives and/or business operations programs is required.
  • Ability to develop and execute on change management and communication strategies is required.
  • Experience in clinical development/operations is preferred.
  • Experience in Quality functions and processes is desired.
  • Broad organizational and business knowledge is required.
  • Business or project management coursework or additional supportive training such as PMP, Six Sigma, Lean, Design Thinking, Agile methodology is desired.
Responsibilities
  • Supports the identification and prioritization of deliverables across clinical departments (i.e., Medical Writing, Biostatistics, Drug Safety, Clinical Science), organizes cross-functional teams and tracks progress against goals and timelines.
  • Understands and advises on functional priorities within the context of enabling larger organizational success.
  • Supports business planning, such as budget review, resource forecasting, goals review, etc.
  • Supports business data collection and analysis, helps track delivery against corporate and department goals and collaborates with Department Heads on Quarterly Business Reviews
  • Problem solves by leveraging understanding of business and functional relationships to activate right people and solutions.
  • Spends time connecting individuals and teams within function, across functions and across the organization.
  • Serves as a thought partner for vision and goal setting and partner with teams to drive functional short-to-long-term business planning and execution.
  • Keeps Department meetings on track with focused agendas and objectives. Takes minutes and tracks deliverables as appropriate, follows up on deliverables as needed.
  • Anticipates needs of CMO and Department Heads and prompts actions and conversations that enhances team success.
  • Helps the CMO and Department Heads balance needs of the function and needs of the overall organization.
  • Advises on new approaches to address organizational needs and complex challenges within Departments and broader organization
  • Identifies opportunities to leverage synergies and eliminate redundancies, drives operational excellence, helps control spend
  • Collaborates with PMO team to align on priorities, processes and tools
  • Represents Clinical Organization in appropriate meetings and committees
  • Must adhere to Iovance Biotherapeutics’ core values, policies, procedures, and business ethics.
  • Perform miscellaneous duties as assigned.
Desired Qualifications
  • MBA preferred
  • Minimum of 10 years in the pharmaceutical industry with responsibilities within a drug development organization with emphasis in Business and Project Management preferred
  • Experience in clinical development/operations preferred
  • Experience in Quality functions and processes desired
  • Business or project management coursework or additional supportive training desired (e.g. PMP, Six Sigma, Lean, Design Thinking, Agile methodology, etc.)
Iovance Biotherapeutics

Iovance Biotherapeutics

View

Iovance Biotherapeutics develops cancer immunotherapies using Tumor Infiltrating Lymphocytes (TIL). It harvests T cells from a patient’s tumor, expands them in the lab, and infuses them back into the patient to attack solid tumors. The therapies are designed as single-treatment treatments without the need for ongoing maintenance. The company differentiates itself by focusing on TIL-based adoptive cell therapy with broad antigen targeting and dedicated cell therapy manufacturing capabilities, including the Iovance Cell Therapy Center (iCTC) to scale production. Its goal is to develop, manufacture, and commercialize proprietary TIL therapies and expand access to cell-based cancer treatments through partnerships and scaled production.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2007

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. treatment centers exceeded 90, targeting 110 by year-end 2026.
  • Q1 2026 Amtagvi revenue reached about $60 million, showing commercial momentum.
  • IOV-5001 and other next-generation TIL programs extend the platform beyond melanoma.

What critics are saying

  • Revenue remains heavily concentrated in Amtagvi, exposing Iovance to single-product execution risk.
  • Autologous cell therapy manufacturing complexity can bottleneck supply, margins, and center throughput.
  • IOV-5001 is early-stage and does not offset near-term dependence on Amtagvi.

What makes Iovance Biotherapeutics unique

  • Iovance leads with autologous **TIL therapy** for heterogeneous solid tumors.
  • Amtagvi is already approved in melanoma across the U.S., Europe, and Australia.
  • The iCTC Philadelphia facility supplies commercial product and clinical TIL therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Iovance Biotherapeutics who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

4%

2 year growth

3%
Stock Titan
Mar 20th, 2026
Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting.

Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company's annual meeting of stockholders, which is anticipated to be held in June 2026. Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board. 03/20/2026 - 05:00 PM Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): (Exact Name of Registrant as Specified in Charter) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Securities registered pursuant to Section 12(b) of the Act: On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the "") of Iovance Biotherapeutics, Inc. (the ""), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company's annual meeting of stockholders (the "") currently anticipated to be held in June 2026. Ms. Yarno will serve out her current term as a director of the Company until the Annual Meeting. The decision to retire and not stand for re-election is not due to a disagreement between the Company and Ms. Yarno on any matter regarding the Company's operations, policies, or practices. The Company thanks Ms. Yarno for her service to the Board. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Faq. What board change did Iovance Biotherapeutics (IOVA) disclose in this 8-K? Iovance Biotherapeutics disclosed that board member Wendy Yarno will retire and not stand for re-election at the upcoming annual meeting. She will remain on the Board until that meeting, and the company expressed appreciation for her service and contributions. When will Iovance Biotherapeutics (IOVA) director Wendy Yarno retire from the Board? Wendy Yarno will retire from the Iovance Biotherapeutics Board at the company's annual meeting of stockholders, currently anticipated for June 2026. She will continue serving as a director until that meeting, providing continuity during the transition period for the Board. Did Wendy Yarno's retirement from Iovance Biotherapeutics (IOVA) involve any disagreement with the company? The company stated that Wendy Yarno's decision to retire and not stand for re-election was not due to any disagreement regarding Iovance's operations, policies, or practices. This language signals an orderly governance transition rather than a dispute-driven departure. What role did Wendy Yarno hold at Iovance Biotherapeutics (IOVA) before announcing retirement? Wendy Yarno served as a member of the Board of Directors of Iovance Biotherapeutics. She notified the Board on March 17, 2026 that she will retire and not stand for re-election at the company's anticipated June 2026 annual stockholder meeting. How did Iovance Biotherapeutics (IOVA) characterize Wendy Yarno's retirement from the Board? Iovance Biotherapeutics indicated that Wendy Yarno's retirement is a personal decision, explicitly noting no disagreement over operations, policies, or practices. The company publicly thanked her for her service, framing the change as a normal board succession event. Filing exhibits & attachments. 3 documents

Yahoo Finance
Mar 7th, 2026
Iovance hits 52-week high as UBS doubles price target to $4

Iovance Biotherapeutics reached a new 52-week high of $5.34 on Friday before closing at $5.13, up 12.01 per cent, following UBS doubling its price target to $4 from $2, though maintaining a neutral rating. Wells Fargo reaffirmed its buy recommendation with a $14 price target. The biopharmaceutical company will participate in Barclays' 28th Annual Global Healthcare Conference on 11 March, where investors will watch for business updates. Iovance reported a 5 per cent wider net loss for 2024 at $390.98 million, whilst total revenues jumped 60.6 per cent to $263.5 million. Fourth-quarter net loss narrowed 8 per cent to $71.9 million, with revenues increasing 17.6 per cent to $86.7 million year-on-year.

Yahoo Finance
Mar 6th, 2026
UBS doubles price target on Iovance Biotherapeutics to $4 following strong Q4 revenue growth

UBS analyst David Dai raised the price target on Iovance Biotherapeutics from $2 to $4 whilst maintaining a Neutral rating. The upgrade follows fundamental improvements in fiscal Q4 2025, though the analyst noted that Amtagvi acceleration remains uncertain. Iovance reported quarterly revenue of $86.77 million, up 17.74% year-over-year and beating estimates by $5.76 million. Full-year product revenue reached $264 million, driven by a 112% increase in Amtagvi revenue. The drug, used for advanced melanoma treatment, saw accelerated uptake across academic and community treatment centres. The commercial-stage biopharmaceutical company develops cell therapies using autologous tumour-infiltrating lymphocytes for metastatic melanoma and other solid tumour cancers.

Yahoo Finance
Feb 28th, 2026
Iovance Biotherapeutics reports 61% annual revenue growth to $264M driven by Amtagvi success

Iovance Biotherapeutics reported 61% year-over-year revenue growth to $264 million for 2025, driven by its cancer treatment Amtagvi. Fourth-quarter product revenue reached $87 million, up 30% from the previous quarter. Amtagvi revenue increased 112% year-over-year. The biotech company achieved several regulatory milestones, including FDA Fast Track Designation for lifileucel in non-small cell lung cancer, supporting a projected 2027 launch. Clinical data showed a 50% confirmed response rate in advanced soft tissue sarcomas. The commercial-stage biopharmaceutical company develops cell therapies using autologous tumour infiltrating lymphocyte for metastatic melanoma and other solid tumour cancers. Management expressed confidence in the company's expanding pipeline and growing network of authorised treatment centres, with international market launches planned ahead.

Yahoo Finance
Feb 25th, 2026
Iovance grows Q4 revenue 30% to $87M, extends cash runway to Q3 2027

Iovance Biotherapeutics reported approximately 30% revenue growth in Q4 2025, with product revenue reaching $87 million. Full-year 2025 revenue totalled $264 million, a 61% increase year-over-year, driven primarily by its Amtagvi product, which saw 112% growth. The company's gross margin improved to 50% in Q4 from 43% in the previous quarter, following full internalisation of manufacturing operations. Iovance ended 2025 with $303 million in cash, extending its runway into Q3 2027. The FDA granted fast track designation for Lifileucel in non-small cell lung cancer. Clinical trials in advanced soft tissue sarcomas showed a 50% confirmed response rate. The company did not provide 2026 revenue guidance and faces challenges scaling community treatment centres beyond academic institutions.